Cambrex Invests in Analytical Laboratory Expansion

On August 30, 2017, Cambrex announced the expansion of its High Point, NC facility with a $3.2-million, 11,000-ft.² analytical laboratory. According to the company, the investment is a response to customer demand for analytical development and validation services in support of current good manufacturing practice (cGMP) products at the clinical stage.

Installation of equipment, including high-performance liquid chromatography (HPLC), mass spectrometers, and support equipment, will start during the third quarter of 2017. Validation and start up is expected to occur in the fourth quarter of 2017. Additionally, the facility’s R&D team will be staffed with 12 new analytical development scientists to accommodate the expansion.

The company acquired the 35,000-ft.² facility, formerly PharmaCore, in October 2016. The site facilitates the production of complex APIs, and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100kg to support Phase I to Phase III clinical trials. This latest expansion brings the investment at the site to more than $5 million since the acquisition by the company and follows the announcement in May 2017 of an increase in pilot-scale manufacturing capacity at the site.

The site is licensed with the US Drug Enforcement Administration to manufacture Schedule II to Schedule V controlled substances. According to the company, the acquisition improved its portfolio of small molecule API services and complements its other manufacturing facilities in the United States and Europe.

Source: Cambrex